MalinJ1

MalinJ1 is a Jersey-registered private holding company rather than an operating drug developer. It is best understood as an investment vehicle tied to Acacia Research's ownership structure and appears to primarily hold an interest in Viamet Pharmaceuticals, a healthcare/biotech asset. Public disclosures indicate that Acacia acquired equity securities of Malin J1 Limited in 2020 and consolidates the entity in its financial statements because it controls MalinJ1. Acacia has also disclosed that its 64% ownership of MalinJ1 gives it an indirect ownership stake in Viamet Pharmaceuticals. Based on available evidence, MalinJ1 itself does not appear to have a standalone therapeutic pipeline, platform, or commercial operating business.